A5064118994- Hemoglobinopathies and Related Disorders
- Gastrointestinal Tumor Research and Treatment
- Acute Myeloid Leukemia Research
- Gastric Cancer Management and Outcomes
- Erythrocyte Function and Pathophysiology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood groups and transfusion
- Gastrointestinal disorders and treatments
- Erythropoietin and Anemia Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hematological disorders and diagnostics
- Iron Metabolism and Disorders
- TGF-β signaling in diseases
- Bone health and treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Neuroendocrine Tumor Research Advances
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Bone and Joint Diseases
- Chronic Disease Management Strategies
- Blood disorders and treatments
- Blood transfusion and management
- Cancer-related gene regulation
Daiichi Sankyo (United States)
2022-2024
Daiichi Sankyo (India)
2024
Bristol-Myers Squibb (United States)
2020
Bristol-Myers Squibb (Switzerland)
2014-2019
Acceleron Pharma (United States)
2012
Medical University of Vienna
2012
Hershey (United States)
2012
Lebanon VA Medical Center
2012
Hospital de Santa Maria
2012
Roswell Park Comprehensive Cancer Center
2010
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 SMAD3 signaling, showed promising results phase 2 study.In double-blind, placebo-controlled, 3 trial, we randomly assigned patients very-low-risk, low-risk, or intermediate-risk (defined according...
Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of units transfused) in such patients.
Rasburicase is effective in controlling plasma uric acid pediatric patients with hematologic malignancies. This study adults evaluated safety of and compared efficacy rasburicase alone followed by oral allopurinol acid.Adults malignancies at risk for hyperuricemia tumor lysis syndrome (TLS) were randomly assigned to (0.20 mg/kg/d intravenously days 1-5), plus (rasburicase 0.20 1 3 300 mg/d 5), or (300 orally 5). Primary variable was response rate defined as percentage achieving maintaining ≤...
This phase IIa study evaluated the safety and tolerability of sotatercept, its effects on bone metabolism haematopoiesis in newly diagnosed relapsed multiple myeloma (MM) patients. Patients were randomized (4:1) to receive four 28-d cycles sotatercept (0·1, 0·3, or 0·5 mg/kg) placebo. also received six combination oral melphalan, prednisolone, thalidomide (MPT). Thirty patients enrolled; placebo 24 sotatercept. Overall, 25% all doses; 71% sotatercept-treated had ≥1 dose interruption mainly...
Ligands of the transforming growth factor-beta superfamily and activin-receptor signaling play an important role in erythropoiesis. Sotatercept, activin receptor type IIA (ActRIIA) ligand trap, is a novel, recombinant, fusion protein comprising extracellular domain human ActRIIA linked to Fc portion immunoglobulin G1. originally developed increase bone mineral density, was noted have robust effects on Here, we evaluated safety, pharmacokinetic properties, pharmacodynamic sotatercept 31...
β-thalassemia, a hereditary blood disorder caused by defective synthesis of hemoglobin β globin chains, leads to ineffective erythropoiesis and chronic anemia that may require transfusions. Sotatercept (ACE-011) acts as ligand trap inhibit negative regulators late-stage in the transforming growth factor superfamily, correcting erythropoiesis. In this phase II, open-label, dose-finding study, 16 patients with transfusion-dependent -thalassemia 30 non-transfusion-dependent β-thalassemia were...
Sotatercept may represent a novel approach to the treatment of chemotherapy-induced anemia (CIA). We report results from two phase 2 randomized studies examining use sotatercept for CIA in patients with metastatic cancer.In study A011-08, breast cancer were 2:2:2:1 receive 0.1, 0.3, or 0.5 mg/kg, placebo, respectively, every 28 days. In ACE-011-NSCL-001, solid tumors treated platinum-based chemotherapy received 15 30 mg 42 The primary endpoint both was hematopoietic response, defined as...
Objectives: DS-6157a is a first-in-class antibody–drug conjugate (ADC) that targets G protein-coupled receptor 20 (GPR20) and comprises humanized anti-GPR20 monoclonal antibody covalently conjugated to an enzyme-cleavable linker, topoisomerase I inhibitor payload (DXd, also known as MAAA-1181a) at drug-to-antibody ratio of ~8. We aimed characterize the pharmacokinetics (PK) (intact ADC) DXd (released payload) through development population PK (PopPK) model evaluate exposure–response (ER)...
87 Background: DS-7300 is an antibody drug conjugate with exatecan derivative payload that targets B7-H3, which overexpressed in various cancers. Initial findings from ongoing phase 1/2 dose escalation study for advanced solid tumors, and dose-expansion studies esophageal squamous cell carcinoma mCRPC (NCT04145622) showed was generally well tolerated early signs of clinical activity (ESMO 2021, abstract 513O). Here, we present preliminary results the pt subset. Methods: This consisted 2...
3002 Background: Cadherin 6 (CDH6) is part of the cadherin family, which involved with cell-cell adhesion, organ development, and epithelial-mesenchymal transition. CDH6 found to be overexpressed in various cancers, particularly RCC OVC. DS-6000a an antibody-drug conjugate, comprised humanized anti-CDH6 IgG1 monoclonal antibody attached a topoisomerase I (TOP1) inhibitor payload via cleavable linker. specifically binds on surface tumor cells internalized upon binding. The then released,...
Abstract Purpose: To evaluate DS-6157a, an antibody–drug conjugate targeting G protein–coupled receptor 20 (GPR20), in gastrointestinal stromal tumors (GIST). Patients and Methods: In this phase I multicenter, open-label, multiple-dose study, patients with previously treated advanced GIST received intravenous DS-6157a on Day 1 of 21-day cycles, a starting dose 1.6 mg/kg. The primary objective evaluated the safety tolerability while determining dose-limiting toxicity (DLT) MTD. Secondary...